[go: up one dir, main page]

CY1115729T1 - Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης - Google Patents

Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης

Info

Publication number
CY1115729T1
CY1115729T1 CY20141100927T CY141100927T CY1115729T1 CY 1115729 T1 CY1115729 T1 CY 1115729T1 CY 20141100927 T CY20141100927 T CY 20141100927T CY 141100927 T CY141100927 T CY 141100927T CY 1115729 T1 CY1115729 T1 CY 1115729T1
Authority
CY
Cyprus
Prior art keywords
tricyclic
union
pharmaceutical use
melatonin
prophylaxis
Prior art date
Application number
CY20141100927T
Other languages
English (en)
Inventor
Osamu Uchikawa
Tatsuki Koike
Yasutaka Hoashi
Takafumi Takai
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1115729T1 publication Critical patent/CY1115729T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια ένωση που παριστάνεται με τον τύπο η οποία είναι χρήσιμη ως ένας παράγοντας για την προφύλαξη ή θεραπευτική αγωγή νόσων που σχετίζονται με τη δράση της μελατονίνης, ή ένα άλας αυτής και τα παρόμοια.
CY20141100927T 2006-06-19 2014-11-07 Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης CY1115729T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006168518 2006-06-19
EP07767453.9A EP2029561B1 (en) 2006-06-19 2007-06-18 Tricyclic compound and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
CY1115729T1 true CY1115729T1 (el) 2017-01-25

Family

ID=38519675

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100927T CY1115729T1 (el) 2006-06-19 2014-11-07 Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης

Country Status (35)

Country Link
US (5) US8030337B2 (el)
EP (1) EP2029561B1 (el)
JP (1) JP5222737B2 (el)
KR (1) KR101442274B1 (el)
CN (1) CN101506181B (el)
AR (1) AR061478A1 (el)
AU (1) AU2007261953B2 (el)
BR (1) BRPI0713743C1 (el)
CA (1) CA2655753C (el)
CL (1) CL2007001779A1 (el)
CO (1) CO6150175A2 (el)
CR (1) CR10524A (el)
CY (1) CY1115729T1 (el)
DK (1) DK2029561T3 (el)
ES (1) ES2523410T3 (el)
GE (1) GEP20125392B (el)
HR (1) HRP20141046T1 (el)
IL (1) IL195639A0 (el)
JO (1) JO2999B1 (el)
MA (1) MA30523B1 (el)
ME (2) ME01998B (el)
MX (1) MX2008015842A (el)
MY (1) MY158069A (el)
NO (1) NO341739B1 (el)
NZ (1) NZ574037A (el)
PE (1) PE20080941A1 (el)
PL (1) PL2029561T3 (el)
PT (1) PT2029561E (el)
RS (1) RS53616B1 (el)
RU (1) RU2456278C2 (el)
SI (1) SI2029561T1 (el)
TW (1) TWI402261B (el)
UA (1) UA99104C2 (el)
WO (1) WO2007148808A1 (el)
ZA (1) ZA200900151B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
BRPI0722057A2 (pt) * 2006-12-28 2014-04-01 Takeda Pharmaceutical Composto, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono, e, uso do composto.
CN103450111B (zh) * 2013-09-04 2015-07-08 温州大学 一种苯并噻唑杂环化合物的绿色合成方法
US20160253891A1 (en) * 2015-02-27 2016-09-01 Elwha Llc Device that determines that a subject may contact a sensed object and that warns of the potential contact
CA3010804A1 (en) * 2016-01-08 2017-07-13 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for autism spectrum disorder
KR20180100627A (ko) 2016-01-08 2018-09-11 다케다 야쿠힌 고교 가부시키가이샤 섬망의 예방 또는 치료제
MX393236B (es) 2016-10-19 2025-03-24 Monsanto Technology Llc Composiciones y métodos para alterar la floración y arquitectura de planta para mejorar el potencial de rendimiento
US20250228798A1 (en) * 2024-01-17 2025-07-17 Rivo Bio, Inc. Indane-, indene-, azaindane-, and azaindene-amines as activators of serotonin receptors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292226C (en) 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
FR2725985B1 (fr) 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19502895A1 (de) 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
US5596019A (en) 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
CA2176854A1 (en) 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5753709A (en) 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
FR2742153B1 (fr) 1995-12-12 1998-02-13 Innothera Lab Sa Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
KR100494214B1 (ko) * 1996-03-08 2005-11-25 다케다 야쿠힌 고교 가부시키가이샤 삼환화합물,그의제조방법및용도
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
SE9802360D0 (sv) * 1998-07-01 1998-07-01 Wikstroem Hakan Vilhelm New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin
WO2001013950A1 (en) * 1999-08-20 2001-03-01 Takeda Chemical Industries, Ltd. Percutaneous absorption agents
JP3633895B2 (ja) * 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
ATE469644T1 (de) * 2000-11-17 2010-06-15 Takeda Pharmaceutical Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
US20060223877A1 (en) 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica

Also Published As

Publication number Publication date
RS53616B1 (sr) 2015-04-30
US20130079374A1 (en) 2013-03-28
TW200815376A (en) 2008-04-01
MA30523B1 (fr) 2009-06-01
ES2523410T3 (es) 2014-11-25
PT2029561E (pt) 2014-11-12
DK2029561T3 (da) 2014-11-10
ME01998B (me) 2015-05-20
JP2009541202A (ja) 2009-11-26
US8030337B2 (en) 2011-10-04
WO2007148808A1 (en) 2007-12-27
AU2007261953B2 (en) 2012-11-08
ZA200900151B (en) 2010-03-31
TWI402261B (zh) 2013-07-21
MY158069A (en) 2016-08-30
BRPI0713743B8 (pt) 2020-05-19
PL2029561T3 (pl) 2015-03-31
KR101442274B1 (ko) 2014-09-22
US8349879B2 (en) 2013-01-08
CA2655753C (en) 2015-08-04
CL2007001779A1 (es) 2008-01-04
NO20090234L (no) 2009-02-12
US8552037B2 (en) 2013-10-08
BRPI0713743A2 (pt) 2012-11-06
US8895591B2 (en) 2014-11-25
HK1130049A1 (en) 2009-12-18
RU2009101299A (ru) 2010-07-27
UA99104C2 (uk) 2012-07-25
IL195639A0 (en) 2009-09-01
AR061478A1 (es) 2008-08-27
GEP20125392B (en) 2012-02-10
NZ574037A (en) 2011-10-28
US8236837B2 (en) 2012-08-07
EP2029561B1 (en) 2014-08-13
CN101506181A (zh) 2009-08-12
BRPI0713743B1 (pt) 2020-03-17
NO341739B1 (no) 2018-01-15
KR20090023701A (ko) 2009-03-05
AU2007261953A1 (en) 2007-12-27
CA2655753A1 (en) 2007-12-27
CR10524A (es) 2009-01-27
ME00582A (en) 2011-12-20
BRPI0713743C1 (pt) 2021-05-25
HRP20141046T1 (hr) 2014-12-19
JP5222737B2 (ja) 2013-06-26
US20090182023A1 (en) 2009-07-16
CO6150175A2 (es) 2010-04-20
US20110196003A1 (en) 2011-08-11
SI2029561T1 (sl) 2014-11-28
PE20080941A1 (es) 2008-09-04
EP2029561A1 (en) 2009-03-04
MX2008015842A (es) 2009-01-09
JO2999B1 (ar) 2016-09-05
RU2456278C2 (ru) 2012-07-20
CN101506181B (zh) 2011-12-07
US20140011849A1 (en) 2014-01-09
US20110190361A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
CY1125051T1 (el) Συντηγμενη ενωση αναστολεα jak ιμιδαζο-πιπεριδινης
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
CY1117078T1 (el) Παραγωγα 1-((5-ετεροαρυλθειαζολ-2-υλ) αμινοκαρβονυλ) πυρρολιδινο-2-καρβοξαμιδης ως αναστολεις φωσφατιδυλινοσιτολ 3-κινασης (ρι3κ) χρησιμα στη θεραπεια πολλαπλασιαστικων νοσων
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
CY1120104T1 (el) Αναστολεις της syk
CY1116399T1 (el) Πυραζολυλαμινοπυριδινες ως αναστολεις της fak
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
ATE517882T1 (de) Chinolinderivate
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
CY1118610T1 (el) Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου
EA201001848A1 (ru) Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
CY1108275T1 (el) Χημικες ενωσεις
DK1853602T3 (da) Kemiske forbindelser
DOP2010000183A (es) Derivados de itazol usados como inhibidores de pi 3-cinasa
CY1115585T1 (el) Κρυσταλλικες μορφες του αλατος του νατριου της 5-αμινο-2,3-διυδροφθαλαζιν-1,4-διονης, οι οποιες περιεχουν φαρμακευτικα σκευασματα και διαδικασιες για την παρασκευη τους
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
CY1111203T1 (el) 4-ανιλινοκινολινο-3-καρβοξαμιδια ως αναστολεις κινασης csf-1r
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
CY1114521T1 (el) Ενωσεις βενζαμιδιου χρησιμες ως αναστολεις αποακετυλασων ιστονων